NLS Pharmaceutics AG: NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience in the Treatment of Narcolepsy Type 1 and Type 2

Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the open label extension (OLE) studyPatients treated with placebo in the randomized

Related Keywords

United States ,Zurich ,Züsz ,Switzerland ,American ,Swiss ,Marianne Lambertson ,George Apostol ,Drug Administration ,European Medicines Agency ,Pharmaceutics Ltd ,American Academy Of Sleep Medicine ,Exchange Commission ,Nasdaq ,Open Label Extension ,Epworth Sleepiness Scale ,Narcolepsy Type ,Chief Medical Officer ,American Academy ,Sleep Medicine ,Idiopathic Hypersomnia ,Orphan Disease Designation ,Mazindol Controlled Release ,Orphan Drug Designations ,Pharmaceutics ,Nnounces ,Pen ,Label ,Extension ,Study ,Month ,Data ,Uilience ,Treatment ,Narcolepsy ,Type ,